MA33768B1 - Triazolopyridines - Google Patents

Triazolopyridines

Info

Publication number
MA33768B1
MA33768B1 MA34899A MA34899A MA33768B1 MA 33768 B1 MA33768 B1 MA 33768B1 MA 34899 A MA34899 A MA 34899A MA 34899 A MA34899 A MA 34899A MA 33768 B1 MA33768 B1 MA 33768B1
Authority
MA
Morocco
Prior art keywords
compounds
preparation
formula
ttk
monopolar
Prior art date
Application number
MA34899A
Other languages
Arabic (ar)
English (en)
Inventor
Volker Schulze
Marcus Koppitz
Dirk Kosemund
Hartmut Schirok
Benjamin Bader
Philip Lienau
Antje Margret Wengner
Hans Briem
Simon Holton
Gerhard Siemeister
Stefan Prechtl
Ulf Bömer
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA33768B1 publication Critical patent/MA33768B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS TRIAZOLOPYRIDINES REPRÉSENTÉS PAR LA FORMULE GÉNÉRALE (I) QUI SONT DES INHIBITEURS DE LA KINASE DE FUSEAU MONOPOLAIRE 1 (MPS-1 OU TTK) : FORMULE (I), DANS LAQUELLE R1, R2, R3, R4 ET R5 SONT TELS QUE DONNÉS DANS LA DESCRIPTION ET LA REVENDICATION. L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS ET DES COMBINAISONS PHARMACEUTIQUES QUI COMPORTENT LESDITS COMPOSÉS, L'UTILISATION DESDITS COMPOSÉS POUR LA FABRICATION D'UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT OU LA PROPHYLAXIE DE MALADIES PROLIFÉRATIVES, AINSI QUE DES COMPOSÉS INTERMÉDIAIRES UTILES DANS LA PRÉPARATION DESDITS COMPOSÉS.
MA34899A 2009-11-30 2012-05-28 Triazolopyridines MA33768B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075535A EP2343297A1 (fr) 2009-11-30 2009-11-30 Triazolopyridines
PCT/EP2010/006994 WO2011063908A1 (fr) 2009-11-30 2010-11-17 Triazolopyridines

Publications (1)

Publication Number Publication Date
MA33768B1 true MA33768B1 (fr) 2012-11-01

Family

ID=42028156

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34899A MA33768B1 (fr) 2009-11-30 2012-05-28 Triazolopyridines

Country Status (36)

Country Link
US (1) US9676766B2 (fr)
EP (2) EP2343297A1 (fr)
JP (1) JP5805653B2 (fr)
KR (1) KR20120115290A (fr)
CN (1) CN102762557B (fr)
AR (1) AR079166A1 (fr)
AU (1) AU2010324155B2 (fr)
BR (1) BR112012012906A2 (fr)
CA (1) CA2781915A1 (fr)
CL (1) CL2012001391A1 (fr)
CR (1) CR20120295A (fr)
CU (1) CU24100B1 (fr)
CY (1) CY1115866T1 (fr)
DK (1) DK2507235T3 (fr)
DO (1) DOP2012000150A (fr)
EA (1) EA022353B1 (fr)
EC (1) ECSP12011935A (fr)
ES (1) ES2525069T3 (fr)
GT (1) GT201200165A (fr)
HN (1) HN2012001162A (fr)
HR (1) HRP20141093T1 (fr)
IL (1) IL219750A (fr)
MA (1) MA33768B1 (fr)
MX (1) MX2012006252A (fr)
MY (1) MY160325A (fr)
NZ (1) NZ600229A (fr)
PE (1) PE20121509A1 (fr)
PH (1) PH12012501055A1 (fr)
PL (1) PL2507235T3 (fr)
PT (1) PT2507235E (fr)
RS (1) RS53670B1 (fr)
SI (1) SI2507235T1 (fr)
TN (1) TN2012000265A1 (fr)
UA (1) UA108486C2 (fr)
WO (1) WO2011063908A1 (fr)
ZA (1) ZA201203806B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
ES2544609T3 (es) 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
CA2821817A1 (fr) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6-imidazopyrazines substituees pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation
CA2821819A1 (fr) 2010-12-17 2012-06-21 Marcus Koppitz Imidazopyrazines 6-substituees pour utilisation en tant qu'inhibiteurs de mps-1 et tkk dans le traitement de troubles hyperproliferatifs
EP2651947B1 (fr) 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH Imidazopyrazines 6-thio substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
JP2014503521A (ja) 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類
JP2013545776A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
WO2012136531A1 (fr) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Imidazopyridines substituées et intermédiaires associés
RS54044B1 (sr) 2011-04-21 2015-10-30 Bayer Intellectual Property Gmbh Triazolopiridini
WO2012160029A1 (fr) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Triazolopyridines substituées
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013135612A1 (fr) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Imidazopyridazines substituées
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
JP2016506921A (ja) 2013-01-30 2016-03-07 バイエル ファーマ アクチエンゲゼルシャフト アミノ置換イソチアゾール
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CA2914516A1 (fr) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridines substituees
AP2015008898A0 (en) * 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
TN2015000543A1 (en) 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP2980088A1 (fr) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Isothiazoles substitués d'amine
CA2944610C (fr) 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indozilines
EP2977375A1 (fr) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Isoxazoles substitués par amino
EP2977377A1 (fr) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Isoxazoles substitués par amino
EP2977376A1 (fr) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Isoxazoles substitués par amino
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
KR101686411B1 (ko) * 2015-12-28 2016-12-14 한국원자력의학원 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
JP7023217B2 (ja) 2017-12-01 2022-02-21 ダイキン工業株式会社 アルカリ接触する表面を有する構成要素
EP3876939A4 (fr) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations
EP3877371A4 (fr) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2022178340A2 (fr) * 2021-02-22 2022-08-25 Orgenesis Inc. Compositions pharmaceutiques comprenant de la ranpirnase
WO2023086319A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
EP1799680A2 (fr) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Derives de triazolopyridine comme agents antibacteriens
WO2007065010A2 (fr) 2005-12-02 2007-06-07 Hif Bio, Inc. Composes anti-angiogenese
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
CA2693232A1 (fr) * 2007-07-18 2009-01-22 Novartis Ag Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (fr) * 2007-08-31 2009-03-05 Dominique Swinnen Composes de triazolopyridine et leur utilisation comme inhibiteurs de ask
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2010092015A1 (fr) 2009-02-10 2010-08-19 Cellzome Limited Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k
SG173610A1 (en) * 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
JP6168773B2 (ja) 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2523949B1 (fr) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Nouveaux dérivés de triazole en tant que modulateurs de la secrétase gamma
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators

Also Published As

Publication number Publication date
PL2507235T3 (pl) 2015-03-31
DOP2012000150A (es) 2012-09-30
JP2013512264A (ja) 2013-04-11
AU2010324155B2 (en) 2015-10-01
CU20120084A7 (es) 2012-10-15
CN102762557B (zh) 2015-10-07
CR20120295A (es) 2012-07-30
CN102762557A (zh) 2012-10-31
CU24100B1 (es) 2015-07-30
UA108486C2 (xx) 2015-05-12
WO2011063908A1 (fr) 2011-06-03
EP2507235B1 (fr) 2014-10-22
NZ600229A (en) 2014-06-27
HK1178153A1 (zh) 2013-09-06
ES2525069T3 (es) 2014-12-17
AU2010324155A1 (en) 2012-06-07
MX2012006252A (es) 2012-09-07
CL2012001391A1 (es) 2012-10-26
PE20121509A1 (es) 2012-11-18
EP2343297A1 (fr) 2011-07-13
HRP20141093T1 (hr) 2015-01-16
AR079166A1 (es) 2011-12-28
BR112012012906A2 (pt) 2017-03-01
IL219750A0 (en) 2012-07-31
EP2507235A1 (fr) 2012-10-10
HN2012001162A (es) 2015-08-10
ECSP12011935A (es) 2012-07-31
US9676766B2 (en) 2017-06-13
MY160325A (en) 2017-02-28
JP5805653B2 (ja) 2015-11-04
RS53670B1 (sr) 2015-04-30
CA2781915A1 (fr) 2011-06-03
GT201200165A (es) 2014-01-03
PH12012501055A1 (en) 2013-02-04
DK2507235T3 (en) 2014-12-15
SI2507235T1 (sl) 2015-01-30
EA201200794A1 (ru) 2013-03-29
CY1115866T1 (el) 2017-01-25
TN2012000265A1 (en) 2013-12-12
IL219750A (en) 2014-02-27
ZA201203806B (en) 2013-07-31
PT2507235E (pt) 2014-12-11
KR20120115290A (ko) 2012-10-17
EA022353B1 (ru) 2015-12-30
US20120328610A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
MA33768B1 (fr) Triazolopyridines
MA34308B1 (fr) Triazolopyridines substituées
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA35444B1 (fr) Ligands du récepteur ep1
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA34806B1 (fr) Compositions pharmaceutiques
MA34917B1 (fr) Dérivés substitués de l'acide 3-hétéroaroylamino-propionique et leur utilisation comme composés pharmaceutiques
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta